Morpholino antisense oligomers: The case for an RNase H-independent structural type

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1489, Issue 1, 1999, Pages 141-158

  Summerton, James ^a  

^a Gene Tools   (United States)

Author keywords

Antisense; Delivery; Efficacy; Morpholino; RNase H independent; Specificity

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RIBONUCLEASE H;

DRUG DELIVERY SYSTEM; DRUG STRUCTURE; DRUG TARGETING; PRIORITY JOURNAL; REVIEW; RNA CLEAVAGE; RNA TRANSLATION;

ALTERNATIVE SPLICING; CELL-FREE SYSTEM; DRUG CARRIERS; DRUG DESIGN; GENE EXPRESSION; GENE TARGETING; HELA CELLS; HUMANS; MORPHOLINES; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDES, ANTISENSE; PROTEIN BIOSYNTHESIS; RIBONUCLEASE H, CALF THYMUS; RNA PROCESSING, POST-TRANSCRIPTIONAL; SUBSTRATE SPECIFICITY; THIONUCLEOTIDES;

EID: 0032699477     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(99)00150-5     Document Type: Review

References (58)

1. Miller P., Yano J., Yano E., Carroll C., Jayaraman K., Ts'o P. Nonionic nucleic acid analogues: synthesis and characterization of dideoxyribonucleoside methylphosphonates. Biochemistry. 18:1979;5134-5142.
2. Blake K., Murakami A., Spitz S., Glave S., Reddy M., Ts'o P., Miller P. Hybridization arrest of globin synthesis in a rabbit reticulocyte lysate and in rabbit reticulocytes by oligodeoxyribonucleoside methylphosphonates. Biochemistry. 24:1985;6139-6145.
3. Stec W., Zon G., Egan W., Stec B. Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides. J. Am. Chem. Soc. 106:1984;6077.
4. Cazenave C., Stein C., Loreau N., Thuong N., Neckers L., Subasinghe C., Helene C., Cohen J., Toulme J. Comparative inhibition of rabbit globin mRNA translation by modified antisense oligodeoxynucleotides. Nucleic Acids Res. 17:1989;4255-4273.
5. Minshull J., Hunt Y. The use of single-stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations. Nucleic Acids Res. 14:1986;6433.
6. Shakin S., Liebhaber S. Destabilization of messenger RNA/complementary DNA duplexes by the elongating 80S ribosome. J. Biol. Chem. 261:1986;16018-16025.
7. Campbell J., Bacon T., Wickstrom E. Oligodeoxynucleotide phosphorothioate stability in subcellular extracts, culture media, sera, and cerebrospinal fluid. J. Biochem. Biophys. Methods. 20:1990;259-267.
8. Monia B., Lesnik E., Gonzalez C., Lima W., McGee D., Guinosso C., Kawasaki A., Cook P., Freier S. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:1993;14514-14522.
9. Stein D., Foster E., Huang S., Weller D., Summerton J. A specificity comparison of four antisense types: morpholino, 2′O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7:1997;151-158.
10. Krieg A., Stein C. Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res. Dev. 5:1995;241.
11. Krieg A., Yi A., Matson S., Waldschmidt T., Bishop G., Teasdale R., Koretzky G., Klinman D. CpG motifs in bacterial DNA trigger direct B cell activation. Nature. 374:1995;546-549.
12. Yaswen P., Stampfer M., Ghosh K., Cohen J. Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells. Antisense Res. Dev. 3:1993;67-77.
13. Too C. Rapid induction of Jak2 and Sp1 in T cells by phosphorothioate oligonucleotides. Antisense Nucleic Acid Drug Dev. 8:1998;87-94.
14. Matsukura M., Zon G., Shinozuka K., Robert-Guroff M., Shimada T., Stein C., Mitsuya H., Wong-Staal F., Cohen J., Broder S. Regulation of viral expression of human immuno-deficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells. Proc. Natl. Acad. Sci. USA. 86:1989;4244.
15. Quote from C. Stein, A. Krieg, Non-antisense effects of oligodeoxynucleotides, in: C. Lichtenstein, W. Nellen (Eds.), Antisense Technology, Ch. 11, IRL Press, Oxford, 1997, p. 260. '. non-antisense effects of PS oligos are also pointed out by a close examination of the oligo ISIS 2922, an 'antisense' oligo with remarkably potent antiviral effects against cytomegalovirus (CMV). ISIS 2922 is reported to have encouraging in vivo efficacy in early clinical trials against CMV retinitis. The sequence of this oligo is quite interesting because it has two atypical CpG motifs: there is a GCG at both the extreme 5′ and 3′ ends (79). Although not fully recognized at the time, published studies on ISIS 2922 demonstrate that its antiviral effect cannot be due to 'antisense' since internal mismatch control oligos lost very little antiviral activity despite a severe drop in the Tm. On the other hand, deletion of a single base from one of the CpG motifs caused a 40% drop in antiviral efficacy, and deletion of a single base from both of the CpG motifs abolished antiviral effect despite little change in the Tm for hybridization to the supposed mRNA target (79)'.
16. P. Nielsen, M. Egholm, R. Berg, O. Buchardt, Peptide nucleic acids (PNA): oligonucleotide analogs with a polyamide backbone, in: S. Crooke, B. Lebleu (Eds.), Antisense Research and Applications, Ch. 19, CRC Press, Boca Raton, FL, 1993, pp. 363-373.
17. Summerton J., Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev. 7:1997;187-195.
18. Summerton J., Stein D., Huang S., Matthews P., Weller D., Partridge M. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. 7:1997;63-70.
19. Taylor M., Paulauskis J., Weller D., Kobzik L. In vitro efficacy of morpholino-modified antisense oligomers directed against tumor necrosis factor-alpha mRNA. J. Biol. Chem. 271:1996;17445-17452.
20. Dominski Z., Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 90:1993;8673-8677.
21. PNAs are commercially available from PerSeptive Biosystems, 500 Old Connecticut Path, Framingham, MA 01701, USA, Tel.: (508) 3837700; Fax: (508) 3837880.
22. Morpholinos are commercially available from GENE TOOLS, P.O.Box 1186, Corvallis, OR 97339, USA, Tel.: (541) 7536330; Fax: (541) 7536360.
23. Milner N., Mir K., Southern E. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotechnol. 15:1997;537-541.
24. Ho S., Bao Y., Lesher T., Malhotra R., Ma L., Fluharty S., Sakai R. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotechnol. 16:1998;59.
25. Chiang M., Chan H., Zounes M., Freier S., Lima W., Bennett C. Antisense oligonucleotides inhibit intercellular adhesion molecule 1 expression by two distinct mechanisms. J. Biol. Chem. 266:1991;18162.
26. Matveeva O., Felden B., Tsodikov A., Johnston J., Monia B., Atkins J., Gesteland R., Frier S. Prediction of antisense oligonucleotide efficacy by in vitro methods. Nat. Biotechnol. 16:1998;1374-1375.
27. Moulds C., Lewis J., Froehler B., Grant D., Huang T., Milligan J., Matteucci M., Wagner R. Site and mechanism of antisense inhibition by C-5 propyne oligonucleotides. Biochemistry. 34:1995;5044-5053.
28. Shoeman R., Hartig R., Huang Y., Grub S., Traub P. Fluorescence microscopic comparison of the binding of phosphodiester and phosphorothioate (antisense) oligodeoxyribonucleotides to subcellular structures, including intermediate filaments, the endoplasmic reticulum, and the nuclear interior. Antisense Nucleic Acid Drug Dev. 7:1997;291-308.
29. Partridge M., Vincent A., Matthews P., Puma J., Stein D., Summerton J. A simple method for delivering morpholino antisense oligos into the cytoplasm of cells. Antisense Nucleic Acid Drug Dev. 6:1996;169-175.
30. Mcneil P., Murphy R., Lanni F., Taylor D. A method for incorporating macromolecules into adherent cells. J. Cell Biol. 98:1984;1556-1564.
31. Hudziak R., Barofsky E., Barofsky D., Weller D.L., Huang S., Weller D.D. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 6:1996;267-272.
32. J. Summerton, Intracellular inactivation of specific nucleotide sequences: a general approach to the treatment of viral diseases and virally-mediated cancers, J. Theor. Biol. 78 (submitted 1973, published 1979) 77-99.
33. Wagner R., Matteucci M., Lewis J., Gutierrez A., Moulds C., Froehler B. Antisense gene inhibition by oligonucleotides containing C-5 propyne pyrimidines. Science. 260:1993;1510-1513.
34. Monia B., Lesnik E., Gonzalez C., Lima W., McGee D., Guinosso C., Kawasaki A., Cook P., Freier S. Evaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:1993;14514-14522.
35. Wagner R., Matteucci M., Grant D., Huang T., Froehler B. Potent and selective inhibition of gene expression by an antisense heptanucleotide. Nat. Biotechnol. 14:1996;840.
36. D. Ecker, Strategies for invasion of RNA secondary structure, S. Crooke, B. Lebleu (Eds.), Antisense Research and Applications, Ch. 21, CRC Press, Boca Raton, FL, 1993, pp. 387-400.
37. Flanagan W., Wagner R., Grant D., Lin K., Matteucci M. Cellular penetration and antisense activity by a phenoxazine-substituted heptanucleotide. Nat. Biotechnol. 17:1999;48.
38. ANTIVIRALS Inc. Technical Report 2, Comparative studies of translation inhibition in reticulocyte lysates, Antisense Res. Dev. 3 (1993) following p. 153.
39. C. Stein, A. Krieg, Non-antisense effects of oligodeoxynucleotides, in: C. Lichtenstein, W. Nellen (Eds.), Antisense Technology, Ch. 11, IRL Press, Oxford, 1997, pp. 241-264.
40. Szymkowski D. Developing antisense oligonucleotides from the laboratory to clinical trials. Drug Discov. Today. 1:1996;415-428.
41. Stein C. Does antisense exist? Nat. Med. 1:1995;1119-1121.
42. Sierakowska H., Sambade M., Agrawal S., Kole R. Repair of thalassemic human beta-globin mRNA in mammalian cells by antisense oligonucleotides. Proc. Natl. Acad. Sci. USA. 93:1996;12840-12844.
43. Kang S., Cho M., Kole R. Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry. 37:1998;6235-6239.
44. Akhtar S., Basu S., Wickstrom E., Juliano R. Interaction of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes). Nucleic Acids Res. 19:1991;5551-5559.
45. Akhtar S., Juliano R. Adsorption and efflux characteristics of modified oligodeoxynucleotides from liposomes. Proc. Am. Assoc. Cancer Res. 32:1991;333.
46. L. Neckers, Cellular internalization of oligodeoxynucleotides, in: S. Crooke, B. Lebleu (Eds.) Antisense Research and Applications, CRC Press, Boca Raton, FL, 1993, pp. 451-460.
47. A. Thierry, A. Rahman, A. Dritschilo, Liposomal delivery as a new approach to transport antisense oligonucleotides, in: R. Erickson, J. Izant (Eds.), Gene Regulation: Biology of Antisense RNA and DNA, Raven Press, New York, 1992, p. 147.
48. Lewis J., Lin K., Kothavale A., Flanagan W., Matteucci M., DePrince R., Mook R., Hendren R., Wagner R. A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA. Proc. Natl. Acad. Sci. USA. 93:1996;3176-3181.
49. Spiller D., Tidd D. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res. Dev. 5:1995;13-21.
50. Okada C., Rechsteiner M. Introduction of macromolecules into cultured mammalian cells by osmotic lysis of pinocytic vesicles. Cell. 29:1982;33-41.
51. Monia B., Johnston J., Geiger T., Muller M., Fabbro D. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase. Nat. Med. 2:1996;668-675.
52. Monia B., Sasmor H., Johnston J., Freier S., Lesnik E., Muller M., Geiger T., Altmann K., Moser H., Fabbro D. Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports an antisense mechanism of action in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;15481-15484.
53. Derossi D., Joliot A., Chassaing G., Prochiantz A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269:1994;10444-10450.
54. Elliot G., O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 88:1997;223-233.
55. Pooga M., Hallbrink M., Zorko M., Langel U. Cell penetration of transportan. FASEB J. 12:1998;67-77.
56. Pooga M., Soomets U., Hallbrink M., Valkna A., Saar K., Rezaei K., Kahl U., Hao J., Xu X., Wiesenfeld-Hallin Z., Hokfelt T., Bartfai T., Langel U. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16:1998;857-861.
57. J. Summerton, D. Weller, Polypeptide composition able to reversibly transit between lipophilic and hydrophilic forms - useful for transporting compounds across lipid layers, Published international patent application, 1997, accession No. 97-549493/50.
58. Summerton J., Weller D. Molecular engine for transporting drugs across cell membranes. Nucleosides Nucleotides. 16:1997;1785-1788.